Recurrent GBM brain tumors with few mutations respond best to immunotherapy
Disagreeing takes up a lot of brain real estate
13 January 2021The dirty life and times of SARS-CoV-2
13 January 2021Recurrent GBM brain tumors with few mutations respond best to immunotherapy
Glioblastoma brain tumors are especially perplexing. Inevitably lethal, the tumors occasionally respond to new immunotherapies after they’ve grown back, enabling up to 20% of patients to live well beyond predicted survival times.
